Ghada Mohamed
@ghadammd_
PGY-1 @LaheyMedicine | loyal friend | she/her |
ID: 1476684099989520386
https://scholar.google.com/citations?user=FhTlgEkAAAAJ&hl=en 30-12-2021 22:38:47
159 Tweet
900 Followers
3,3K Following
So grateful for this (unlikely) collaboration of UNC Gastroenterology and Duke GI at ACG this year! All credit to Andrew Gilman and Todd H Baron MD, MASGE for helping me understand incredibly advanced endoscopic techniques. So fortunate to have you as my mentors!
Happy Halloween from the Duke Pharmacology & Cancer Biology Department costume competition - we won! We are the “cells of the intestinal epithelium and supporting niche” (similar to 2018 Koch Institute at MIT Omer Yilmaz lab retreat but with some new cell types). Duke GI
Check out our new paper on the utility and use of fecal biomarkers in monitoring Crohn’s disease and discriminating activity. Was a pleasure working on this with Jonathan Segal and collaborators! mdpi.com/2227-9059/11/5…
The answers for this week are out! Check out the tweetorial on Mirizzi syndrome made by @ghmm47 and me along with Rashmi Advani, MD, ABOM-D Time to head over to CrushingGIBoards now!
Happy weekend! Let's wrap this week with this summary slide on Mirizzi syndrome by board member Tanisha Kalra, MD Don't forget to save it for a quick review before boards! #MedTwitter #MedEd #GITwitter
My first (hopefully out of many) VideoGIE Journal article! All thanks to Todd H Baron MD, MASGE and Andrew Gilman. Cholangioscopic recanalization of a completely obstructed anastomotic ... sciencedirect.com/science/articl…
Happy to have our research recognized as a presidential poster at #ACG2023. All thanks to Danting Jiang, Dr. Jillian Hurst, PhD, Dr. Matthew Kelly, and Dr. Neil Surana. Special thanks to Dr. Jatin Roper for leading this project. Read more here: cdmcd.co/KpE3P5
Happy to see our research recognized by Cedars-Sinai Academic Medicine! Excited to share more about our work Digestive Disease Week!
Our paper in Annals of Int Med on rapidly changing trends in GLP-1RA use - Use has dramatically increased since 2011 particularly after 2020 - Use in obesity without diabetes has tripled - Off-label use has increased from from 0.21% in 2019 to 0.37% in 2023 - Semaglutide (Ozempic,
Thrilled to share our findings on early-stage pancreatic cancer staging, published on JAMA: lymph nodes often missed on preop imaging with huge impact on treatment and survival - Srinivas Gaddam, MD, MPH Ghada Mohamed Cedars-Sinai